Author | Mark Packer, MD, FACS, CPI


Pearls and pitfalls for principal investigators

Interested in becoming a principal researcher? Read this first.

Directly targeting pathology: A novel approach to treating glaucoma

Rho kinase inhibitors are intriguing in that they work directly on the pathogenic mechanism of abnormally elevated IOP, increased resistance to trabecular outflow.

New content coming soon, please check back later.